View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsRadius Health 과거 순이익 실적과거 기준 점검 0/6핵심 정보28.59%순이익 성장률30.13%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률35.32%자기자본이익률n/a순이익률-30.72%최근 순이익 업데이트30 Jun 2022최근 과거 실적 업데이트Reported Earnings • Aug 10Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.27 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$58.3m (up 13% from 2Q 2021). Net loss: US$12.7m (loss narrowed 24% from 2Q 2021). Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 13%, compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.39 loss per share (down from US$0.34 loss in 1Q 2021). Revenue: US$43.2m (down 23% from 1Q 2021). Net loss: US$18.3m (loss widened 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 65%. Over the next year, revenue is forecast to grow 13%, compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 26Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$1.49 loss per share (up from US$2.35 loss in FY 2020). Revenue: US$230.0m (down 3.6% from FY 2020). Net loss: US$70.2m (loss narrowed 36% from FY 2020). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 6.0%, compared to a 185% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$56.8m (down 27% from 3Q 2020). Net loss: US$22.0m (loss widened 250% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$51.8m (up 3.4% from 2Q 2020). Net loss: US$16.8m (loss narrowed 62% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • May 09First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$56.3m (up 17% from 1Q 2020). Net loss: US$15.7m (loss narrowed 58% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updatesSeeking Alpha • Mar 14Radius Recycling's Surge Justifies A ReevaluationSummary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking AlphaSeeking Alpha • Feb 25Radius Recycling Will Benefit From Steel TariffsSummary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking AlphaSeeking Alpha • Jul 16Radius Recycling Stays In The Scrap PileSummary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking AlphaSeeking Alpha • Jun 03Radius Recycling: An Attractive, But Volatile, Play On A Cleaner FutureSummary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking AlphaSeeking Alpha • Aug 11Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtypeThe U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS). Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11Reported Earnings • Aug 10Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.27 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$58.3m (up 13% from 2Q 2021). Net loss: US$12.7m (loss narrowed 24% from 2Q 2021). Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 13%, compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Price Target Changed • Jun 24Price target increased to US$10.00Up from US$9.00, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of US$10.11. The company is forecast to post a net loss per share of US$0.26 next year compared to a net loss per share of US$1.49 last year.Buying Opportunity • Jun 10Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be US$9.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 11% in a year. Earnings is forecast to grow by 93% in the next year.Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$238.0m to US$234.2m. 2022 losses expected to reduce from -US$0.32 to -US$0.27 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target broadly unchanged at US$9.43. Share price rose 11% to US$6.25 over the past week.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.39 loss per share (down from US$0.34 loss in 1Q 2021). Revenue: US$43.2m (down 23% from 1Q 2021). Net loss: US$18.3m (loss widened 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 65%. Over the next year, revenue is forecast to grow 13%, compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Breakeven Date Change • May 06Forecast breakeven date moved forward to 2022The 7 analysts covering Radius Health previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$2.04m in 2022. Earnings growth of 61% is required to achieve expected profit on schedule.Major Estimate Revision • Apr 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.03 to -US$0.06 per share. Revenue forecast unchanged at US$247.5m. Biotechs industry in the US expected to see average net income decline 47% next year. Consensus price target of US$10.14 unchanged from last update. Share price fell 12% to US$6.80 over the past week.Major Estimate Revision • Apr 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.03 to -US$0.05 per share. Revenue forecast unchanged at US$247.6m. Biotechs industry in the US expected to see average net income decline 45% next year. Consensus price target of US$10.14 unchanged from last update. Share price fell 6.7% to US$7.40 over the past week.Major Estimate Revision • Mar 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$245.8m to US$248.9m. Forecast EPS reduced from -US$0.01 to -US$0.11 per share. Biotechs industry in the US expected to see average net income decline 38% next year. Consensus price target of US$10.00 unchanged from last update. Share price was steady at US$8.45 over the past week.Reported Earnings • Feb 26Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$1.49 loss per share (up from US$2.35 loss in FY 2020). Revenue: US$230.0m (down 3.6% from FY 2020). Net loss: US$70.2m (loss narrowed 36% from FY 2020). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 6.0%, compared to a 185% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Breakeven Date Change • Feb 26Forecast breakeven date moved forward to 2022The 6 analysts covering Radius Health previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$276.7k in 2022. Earnings growth of 60% is required to achieve expected profit on schedule.Seeking Alpha • Feb 24Reevaluating Radius HealthRadius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.Breakeven Date Change • Jan 18Forecast breakeven date pushed back to 2023The 7 analysts covering Radius Health previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 73% per year to 2022. The company is expected to make a profit of US$25.7m in 2023. Average annual earnings growth of 58% is required to achieve expected profit on schedule.Price Target Changed • Dec 09Price target decreased to US$20.50Down from US$23.86, the current price target is an average from 8 analysts. New target price is 156% above last closing price of US$8.01. Stock is down 43% over the past year. The company is forecast to post a net loss per share of US$1.33 next year compared to a net loss per share of US$2.35 last year.Breakeven Date Change • Dec 07Forecast breakeven date pushed back to 2023The 8 analysts covering Radius Health previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 83% per year to 2022. The company is expected to make a profit of US$32.6m in 2023. Average annual earnings growth of 76% is required to achieve expected profit on schedule.Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$56.8m (down 27% from 3Q 2020). Net loss: US$22.0m (loss widened 250% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Price Target Changed • Oct 22Price target increased to US$23.86Up from US$22.14, the current price target is an average from 7 analysts. New target price is 23% above last closing price of US$19.40. Stock is up 43% over the past year. The company is forecast to post a net loss per share of US$0.93 next year compared to a net loss per share of US$2.35 last year.Executive Departure • Aug 27CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer James Chopas has left the companyOn the 26th of August, James Chopas' tenure as CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer ended after less than a year in the role. As of June 2021, James still personally held 4.37k shares (US$80k worth at the time). A total of 7 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Price Target Changed • Aug 11Price target decreased to US$22.29Down from US$24.75, the current price target is an average from 8 analysts. New target price is 62% above last closing price of US$13.75. Stock is up 11% over the past year.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$51.8m (up 3.4% from 2Q 2020). Net loss: US$16.8m (loss narrowed 62% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.69 to -US$0.81 per share. Revenue forecast unchanged at US$262.9m. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target broadly unchanged at US$24.75. Share price was steady at US$20.30 over the past week.Major Estimate Revision • May 15Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$267.2m to US$264.1m. 2021 losses expected to reduce from -US$0.97 to -US$0.74 per share. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$24.63 unchanged from last update. Share price was steady at US$20.95 over the past week.Reported Earnings • May 09First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$56.3m (up 17% from 1Q 2020). Net loss: US$15.7m (loss narrowed 58% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Major Estimate Revision • Mar 25Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$261.7m to US$266.6m. Forecast EPS reduced from -US$0.85 to -US$0.95 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$23.50 to US$24.50. Share price was steady at US$23.02 over the past week.Major Estimate Revision • Mar 13Analysts update estimatesThe company's losses in 2021 are expected to worsen with analysts lowering their consensus EPS forecasts from -US$0.74 to -US$0.85. Revenue estimate was approximately flat at US$261.7m. The Biotechs industry in the US is expected to see an average net income growth of 4.2% next year. The consensus price target of US$23.50 was unchanged from the last update. Share price is up 6.7% to US$22.90 over the past week.Reported Earnings • Feb 27Full year 2020 earnings released: US$2.35 loss per share (vs US$2.89 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$238.6m (up 38% from FY 2019). Net loss: US$109.2m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectationsRevenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 8.4%, compared to a 1,120% growth forecast for the Biotechs industry in the US.분석 기사 • Feb 23When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...Is New 90 Day High Low • Feb 06New 90-day high: US$22.94The company is up 69% from its price of US$13.59 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$65.30 per share.Price Target Changed • Jan 08Price target raised to US$22.00Up from US$20.25, the current price target is an average from 7 analysts. The new target price is close to the current share price of US$21.99. As of last close, the stock is up 7.3% over the past year.Is New 90 Day High Low • Jan 07New 90-day high: US$21.60The company is up 60% from its price of US$13.50 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$63.35 per share.분석 기사 • Jan 01How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...Is New 90 Day High Low • Dec 17New 90-day high: US$18.54The company is up 48% from its price of US$12.55 on 17 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$111 per share.Is New 90 Day High Low • Nov 11New 90-day high: US$14.86The company is up 22% from its price of US$12.14 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$90.19 per share.Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 5.9%. Earnings per share (EPS) also missed analyst estimates by 34%. Over the next year, revenue is forecast to grow 16%, compared to a 310% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.14 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$77.8m (up 66% from 3Q 2019). Net loss: US$6.29m (loss narrowed 79% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 27New 90-day high: US$13.88The company is up 4.0% from its price of US$13.30 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$92.96 per share.Is New 90 Day High Low • Sep 29New 90-day low: US$10.80The company is down 23% from its price of US$13.99 on 01 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$86.43 per share.매출 및 비용 세부 내역Radius Health가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:RDUS 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 22223-6912912131 Mar 22217-7312712231 Dec 21230-7013013130 Sep 21228-7613812830 Jun 21249-6013413431 Mar 21247-8714015131 Dec 20239-10914315930 Sep 20232-11314415830 Jun 20200-13614814931 Mar 20191-12815013131 Dec 19173-13315511530 Sep 19152-14916310430 Jun 19133-16917010031 Mar 19115-2031799931 Dec 1899-2211869830 Sep 1872-2511939730 Jun 1858-2591979131 Mar 1837-2591998431 Dec 1722-2541898130 Sep 1714-2361678230 Jun 171-2241388931 Mar 170-1991049731 Dec 160-1838010530 Sep 160-1636210430 Jun 160-145519531 Mar 160-125408431 Dec 150-1023168양질의 수익: RDUS 은(는) 현재 수익성이 없습니다.이익 마진 증가: RDUS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RDUS는 수익성이 없지만 지난 5년 동안 연평균 28.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RDUS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RDUS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RDUS의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/08/11 14:55종가2022/08/11 00:00수익2022/06/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Radius Health, Inc.는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gregory HarrisonBofA Global ResearchJohn NewmanCanaccord GenuityMara GoldsteinCantor Fitzgerald & Co.9명의 분석가 더 보기
Reported Earnings • Aug 10Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.27 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$58.3m (up 13% from 2Q 2021). Net loss: US$12.7m (loss narrowed 24% from 2Q 2021). Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 13%, compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.39 loss per share (down from US$0.34 loss in 1Q 2021). Revenue: US$43.2m (down 23% from 1Q 2021). Net loss: US$18.3m (loss widened 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 65%. Over the next year, revenue is forecast to grow 13%, compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 26Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$1.49 loss per share (up from US$2.35 loss in FY 2020). Revenue: US$230.0m (down 3.6% from FY 2020). Net loss: US$70.2m (loss narrowed 36% from FY 2020). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 6.0%, compared to a 185% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$56.8m (down 27% from 3Q 2020). Net loss: US$22.0m (loss widened 250% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$51.8m (up 3.4% from 2Q 2020). Net loss: US$16.8m (loss narrowed 62% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$56.3m (up 17% from 1Q 2020). Net loss: US$15.7m (loss narrowed 58% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Seeking Alpha • Mar 14Radius Recycling's Surge Justifies A ReevaluationSummary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25Radius Recycling Will Benefit From Steel TariffsSummary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16Radius Recycling Stays In The Scrap PileSummary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03Radius Recycling: An Attractive, But Volatile, Play On A Cleaner FutureSummary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtypeThe U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS). Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11
Reported Earnings • Aug 10Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.27 loss per share (up from US$0.35 loss in 2Q 2021). Revenue: US$58.3m (up 13% from 2Q 2021). Net loss: US$12.7m (loss narrowed 24% from 2Q 2021). Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 13%, compared to a 51% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Price Target Changed • Jun 24Price target increased to US$10.00Up from US$9.00, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of US$10.11. The company is forecast to post a net loss per share of US$0.26 next year compared to a net loss per share of US$1.49 last year.
Buying Opportunity • Jun 10Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 16%. The fair value is estimated to be US$9.26, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 11% in a year. Earnings is forecast to grow by 93% in the next year.
Major Estimate Revision • May 20Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$238.0m to US$234.2m. 2022 losses expected to reduce from -US$0.32 to -US$0.27 per share. Biotechs industry in the US expected to see average net income decline 52% next year. Consensus price target broadly unchanged at US$9.43. Share price rose 11% to US$6.25 over the past week.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.39 loss per share (down from US$0.34 loss in 1Q 2021). Revenue: US$43.2m (down 23% from 1Q 2021). Net loss: US$18.3m (loss widened 16% from 1Q 2021). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 65%. Over the next year, revenue is forecast to grow 13%, compared to a 41% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Breakeven Date Change • May 06Forecast breakeven date moved forward to 2022The 7 analysts covering Radius Health previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$2.04m in 2022. Earnings growth of 61% is required to achieve expected profit on schedule.
Major Estimate Revision • Apr 27Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.03 to -US$0.06 per share. Revenue forecast unchanged at US$247.5m. Biotechs industry in the US expected to see average net income decline 47% next year. Consensus price target of US$10.14 unchanged from last update. Share price fell 12% to US$6.80 over the past week.
Major Estimate Revision • Apr 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.03 to -US$0.05 per share. Revenue forecast unchanged at US$247.6m. Biotechs industry in the US expected to see average net income decline 45% next year. Consensus price target of US$10.14 unchanged from last update. Share price fell 6.7% to US$7.40 over the past week.
Major Estimate Revision • Mar 12Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from US$245.8m to US$248.9m. Forecast EPS reduced from -US$0.01 to -US$0.11 per share. Biotechs industry in the US expected to see average net income decline 38% next year. Consensus price target of US$10.00 unchanged from last update. Share price was steady at US$8.45 over the past week.
Reported Earnings • Feb 26Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: US$1.49 loss per share (up from US$2.35 loss in FY 2020). Revenue: US$230.0m (down 3.6% from FY 2020). Net loss: US$70.2m (loss narrowed 36% from FY 2020). Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Over the next year, revenue is forecast to grow 6.0%, compared to a 185% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Feb 26Forecast breakeven date moved forward to 2022The 6 analysts covering Radius Health previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of US$276.7k in 2022. Earnings growth of 60% is required to achieve expected profit on schedule.
Seeking Alpha • Feb 24Reevaluating Radius HealthRadius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Breakeven Date Change • Jan 18Forecast breakeven date pushed back to 2023The 7 analysts covering Radius Health previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 73% per year to 2022. The company is expected to make a profit of US$25.7m in 2023. Average annual earnings growth of 58% is required to achieve expected profit on schedule.
Price Target Changed • Dec 09Price target decreased to US$20.50Down from US$23.86, the current price target is an average from 8 analysts. New target price is 156% above last closing price of US$8.01. Stock is down 43% over the past year. The company is forecast to post a net loss per share of US$1.33 next year compared to a net loss per share of US$2.35 last year.
Breakeven Date Change • Dec 07Forecast breakeven date pushed back to 2023The 8 analysts covering Radius Health previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 83% per year to 2022. The company is expected to make a profit of US$32.6m in 2023. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
Reported Earnings • Nov 10Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: US$56.8m (down 27% from 3Q 2020). Net loss: US$22.0m (loss widened 250% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Oct 22Price target increased to US$23.86Up from US$22.14, the current price target is an average from 7 analysts. New target price is 23% above last closing price of US$19.40. Stock is up 43% over the past year. The company is forecast to post a net loss per share of US$0.93 next year compared to a net loss per share of US$2.35 last year.
Executive Departure • Aug 27CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer James Chopas has left the companyOn the 26th of August, James Chopas' tenure as CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer ended after less than a year in the role. As of June 2021, James still personally held 4.37k shares (US$80k worth at the time). A total of 7 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Price Target Changed • Aug 11Price target decreased to US$22.29Down from US$24.75, the current price target is an average from 8 analysts. New target price is 62% above last closing price of US$13.75. Stock is up 11% over the past year.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$51.8m (up 3.4% from 2Q 2020). Net loss: US$16.8m (loss narrowed 62% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 19Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.69 to -US$0.81 per share. Revenue forecast unchanged at US$262.9m. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target broadly unchanged at US$24.75. Share price was steady at US$20.30 over the past week.
Major Estimate Revision • May 15Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from US$267.2m to US$264.1m. 2021 losses expected to reduce from -US$0.97 to -US$0.74 per share. Biotechs industry in the US expected to see average net income decline 11% next year. Consensus price target of US$24.63 unchanged from last update. Share price was steady at US$20.95 over the past week.
Reported Earnings • May 09First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$56.3m (up 17% from 1Q 2020). Net loss: US$15.7m (loss narrowed 58% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Mar 25Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from US$261.7m to US$266.6m. Forecast EPS reduced from -US$0.85 to -US$0.95 per share. Biotechs industry in the US expected to see average net income growth of 4.2% next year. Consensus price target up from US$23.50 to US$24.50. Share price was steady at US$23.02 over the past week.
Major Estimate Revision • Mar 13Analysts update estimatesThe company's losses in 2021 are expected to worsen with analysts lowering their consensus EPS forecasts from -US$0.74 to -US$0.85. Revenue estimate was approximately flat at US$261.7m. The Biotechs industry in the US is expected to see an average net income growth of 4.2% next year. The consensus price target of US$23.50 was unchanged from the last update. Share price is up 6.7% to US$22.90 over the past week.
Reported Earnings • Feb 27Full year 2020 earnings released: US$2.35 loss per share (vs US$2.89 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$238.6m (up 38% from FY 2019). Net loss: US$109.2m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Feb 27Revenue beats expectationsRevenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 8.4%, compared to a 1,120% growth forecast for the Biotechs industry in the US.
분석 기사 • Feb 23When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Is New 90 Day High Low • Feb 06New 90-day high: US$22.94The company is up 69% from its price of US$13.59 on 06 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$65.30 per share.
Price Target Changed • Jan 08Price target raised to US$22.00Up from US$20.25, the current price target is an average from 7 analysts. The new target price is close to the current share price of US$21.99. As of last close, the stock is up 7.3% over the past year.
Is New 90 Day High Low • Jan 07New 90-day high: US$21.60The company is up 60% from its price of US$13.50 on 08 October 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$63.35 per share.
분석 기사 • Jan 01How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...
Is New 90 Day High Low • Dec 17New 90-day high: US$18.54The company is up 48% from its price of US$12.55 on 17 September 2020. The American market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$111 per share.
Is New 90 Day High Low • Nov 11New 90-day high: US$14.86The company is up 22% from its price of US$12.14 on 12 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$90.19 per share.
Analyst Estimate Surprise Post Earnings • Nov 07Revenue and earnings miss expectationsRevenue missed analyst estimates by 5.9%. Earnings per share (EPS) also missed analyst estimates by 34%. Over the next year, revenue is forecast to grow 16%, compared to a 310% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 07Third quarter 2020 earnings released: US$0.14 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$77.8m (up 66% from 3Q 2019). Net loss: US$6.29m (loss narrowed 79% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 27New 90-day high: US$13.88The company is up 4.0% from its price of US$13.30 on 28 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$92.96 per share.
Is New 90 Day High Low • Sep 29New 90-day low: US$10.80The company is down 23% from its price of US$13.99 on 01 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$86.43 per share.